MAX B KELZ
Medical Practice in Merion Station, PA
License number
Pennsylvania MD424056
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Merion Station, PA 19066
Personal information
See more information about MAX B KELZ at radaris.comName
Address
Phone
289 N Highland Ave, Merion Station, PA 19066
1500 Locust St #3504, Philadelphia, PA 19102
1740 Oakwood Ter, Narberth, PA 19072
289 Highland Ave N, Merion Station, PA 19066
289 N Highland Ave, Merion Station, PA 19066
Professional information
In Situ Cloning From Pathological Tissue Specimens
US Patent:
2013018, Jul 25, 2013
Filed:
Mar 21, 2013
Appl. No.:
13/848416
Inventors:
The Trusfees of the University of Pennsylvania - Philadelphia PA, US
Max B. Kelz - Merion Station PA, US
Max B. Kelz - Merion Station PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
The present invention pertains to methods related to cloning nucleic acids from biological samples, particularly pathological tissue samples. This method includes hybridizing a population of oligonucleotide sequence probes comprising degenerate sequence tags to a fixed tissue, isolating the hybridized oligonucleotide sequence probes and amplifying the sequence tags in the hybridized oligonucleotide sequence probes. This method can be utilized to identify genes associated with disease and to quantitate the expression of disease-related transcripts. The method can also be used to identify truncated mRNAs.
In Situ Cloning From Pathological Tissue Specimens
US Patent:
8530196, Sep 10, 2013
Filed:
Apr 9, 2007
Appl. No.:
11/784677
Inventors:
James H. Eberwine - Philadelphia PA, US
Max B. Kelz - Merion Station PA, US
Max B. Kelz - Merion Station PA, US
Assignee:
The Trustees of the Univeristy of Pennsylvania - Philadelphia PA
International Classification:
C12P 19/34
US Classification:
435 912
Abstract:
The present invention pertains to methods related to cloning nucleic acids from biological samples, particularly pathological tissue samples. This method includes hybridizing a population of oligonucleotide sequence probes comprising degenerate sequence tags to a fixed tissue, isolating the hybridized oligonucleotide sequence probes and amplifying the sequence tags in the hybridized oligonucleotide sequence probes. This method can be utilized to identify genes associated with disease and to quantitate the expression of disease-related transcripts. The method can also be used to identify truncated mRNAs.